Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report.

HIV 和 COVID 19 感染患者多重耐药鲍曼不动杆菌引起的呼吸机相关性肺炎 （ VAP ） 和胸膜脓胸 ： 一例。

• 发表时间: 2023 Jun
• 来源期刊: Infect Med (Beijing)
• DOI: 10.1016/j.imj.2023.02.004
• PMID: 38013739
• 文章类型: Case Reports
• 作者列表: Passerotto RA,Lamanna F,Farinacci D,Dusina A,Di Giambenedetto S,Ciccullo A,Borghetti A

关键词: Acinetobacter baumannii; HIV; SARS-CoV-2; cefiderocol; colistin

Abstract

We analyzed the case of a 49-year-old woman with HIV infection off-therapy with poor viro-immunological compensation, not vaccinated for SARS-COV-2, hospitalized for lobar pneumonia and severe COVID19-related respiratory failure in intensive care unit (ICU). The hospitalization was complicated by bacteraemic ventilator-associated pneumonia (VAP) caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) isolated on pleural fluid culture, treated with colistin and cefiderocol for about 3 weeks. The molecular research of MDR-AB on transtracheal aspirate was negative following this therapy. The aim is to show the safety, efficacy and tolerability of colistin-based combination therapy with cefiderocol for Acinetobacter baumannii infection in HIV-infected patient.

摘要

我们分析了一名49岁的HIV感染女性的病例，该患者接受了较差的病毒免疫补偿，未接种SARS-COV-2疫苗，因重症监护病房（ICU）大叶性肺炎和严重COVID19相关呼吸衰竭住院。住院并发由胸水培养分离的多药耐药鲍曼不动杆菌（MDR-AB）引起的细菌性呼吸机相关性肺炎（VAP）。用粘菌素和头孢地洛治疗约3周。经气管抽吸物MDR-AB的分子研究为阴性。目的是为了显示安全，粘菌素与头孢地洛联合治疗对HIV感染患者鲍曼不动杆菌感染的疗效和耐受性。